Pharmacokinetic-pharmacodynamic modelling of the anti-lipolytic and anti-ketotic effects of the adenosine A1-receptor agonist N6-(p-sulphophenyl)adenosine in rats

British Journal of Pharmacology

Volumn 122, Issue 3, 1997, Pages 525-533

  Van Schaick, E A ^a   De Greef, H J M M ^a   Langemeijer, M W E ^a   Sheehan, M J ^b   IJzerman, A P ^a   Danhof, M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Adenosine A1 receptor; Fatty acids; Heart rate; Ketone body; Lipolysis; N6 (p sulphophenyl)adenosine; Pharmacodynamic; Pharmacokinetic; Tissue selectivity

Indexed keywords

3 HYDROXYBUTYRIC ACID; 6 N (4 SULFOPHENYL)ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE DERIVATIVE; FATTY ACID;

ANIMAL EXPERIMENT; ARTERIAL BLOOD; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENCY; FATTY ACID BLOOD LEVEL; HEART RATE; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; KETOACIDOSIS; LIPOLYSIS; MALE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT;

3-HYDROXYBUTYRIC ACID; ADENOSINE; ANIMALS; ANTILIPEMIC AGENTS; BLOOD PRESSURE; BLOOD PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FATTY ACIDS, NONESTERIFIED; HEART RATE; HYDROXYBUTYRATES; LIPOLYSIS; MALE; MODELS, BIOLOGICAL; PROTEIN BINDING; RATS; RATS, WISTAR; RECEPTORS, PURINERGIC P1;

EID: 0030962760     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701412     Document Type: Article

References (34)

1. AKAIKE, H. (1974). A new look at the statistical model identification. IEEE Trans. Automat. Control., AC-19, 716-723.
2. BELL, P.A., DEEMS, R.O., EVANS, J.L., HONER, C.M. & YOUNG, D.A. (1994). Effects of WAG994 on lipid and glucose metabolism in vitro and in vivo. Diabetes, 43, A44.
3. DAYNEKA, N.L., GARG, V. & JUSKO, W.J. (1993). Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokin. Biopharm., 21, 457-478.
4. 1-adenosine receptors in guinea pig atrioventricular node. Am. J. Physiol., 262, H661-H671.
5. FERRANNINI, E., BARRET, E.J. & BEVILACQUA, S. (1983). Effect of fatty acids on glucose production and utilization in man. J. Clin. Invest., 72, 1737-1747.
6. 1 receptors in adipocytes in the treatment of non-insulin dependent diabetes mellitus. Drug Dev. Res., 32, 126.
7. FULCHER, G.R., WALKER, M., CATALANO, C., AGIUS, L. & ALBERTI, K.G.M.M. (1992). Metabolic effects of suppression of nonesterified fatty acids level with acipimox in obese NIDDM subjects. Diabetes, 41, 1400-1408.
8. GARDNER, C.J., TWISSELL, D.J., COATES, J. & STRONG, P. (1994). The effects of GR79236 on plasma fatty acid concentrations, heart rate and blood pressure in the conscious rat. Eur. J. Pharmacol., 257, 117-121.
9. GIBALDI, M. & PERRIER, D. (1982). Non-compartmental analysis based on statistical moment theory. In Pharmacokinetics (2nd edition) ed. Gibaldi, M. & Perrier, D. pp. 409-424. New York: Marcel Dekker.
10. GURDEN, M.F., COATES, J., ELLIS, F., EVANS, B., FOSTER, M., HORNBY, E., KENNEDY, I., MARTIN, D.P., STRONG, P., VARDEY, C.J. & WHEELDON, A. (1993). Functional characterisation of three adenosine receptors. Br. J. Pharmacol., 109, 693-698.
11. HOFFMAN, B.B., DALL'AGLIO, E., HOLLENBECK, C., CHANG, H. & REAVEN, G.M. (1986). Suppression of fatty acids and triglycerides in normal and hypertriglyceridemic rats by the adenosine receptor agonist phenylisopropyladenosine. J. Pharmacol. Exp. Ther., 239, 715-718.
12. HOLFORD, N.H.G. (1986). Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin. Pharmacokinet., 11, 486-504.
13. HOLFORD, N.H.G. (1992). Parametric models of the time course of drug action. In The In Vivo Study of Drug Action. ed. Van Boxtel, C.J., Holford, N.H.G. & Danhof, M. pp. 61-69. Amsterdam: Elsevier.
14. HOLFORD, N.H.G. & SHEINER, L.B. (1982). Kinetics of pharmacological response. Pharmacol. Ther., 16, 143-166.
15. 6-sulfoalkyl derivatives of adenosine: Water-soluble and peripherally selective adenosine agonists. J. Med. Chem., 35, 4143-4149.
16. JUSKO, W.J. & KO, H.C. (1994). Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin. Pharmacol. Ther., 56, 406-419.
17. KENAKIN, T. (1993). Pharmacological Analysis of Drug-Receptor Interaction. New York: Raven Press.
18. 3 receptors exist? Gen. Pharmacol., 23, 303-307.
19. 1 adenosine receptors. Naunyn-Schmiedeberg's Arch. Pharmacol., 340, 679-683.
20. LEVY, G. (1994). Mechanism-based pharmacodynamic modeling. Clin. Pharmacol. Ther., 56, 356-358.
21. 1 adenosine receptors: Persistent activation reveals spare receptors. Mol. Pharmacol., 30, 403-409.
22. LONDOS, C., HONNER, R.C. & DHILLON, G.S. (1980). c-AMP dependent protein kinase and lipolysis in rat adipocytes. III. Multiple modes of insulin regulation of lipolysis and regulation of insulin responses by adenylate cyclase. J. Biol. Chem., 260, 15139-15145.
23. 2A receptor agonist CGS 21680C in conscious normotensive rats. Br. J. Pharmacol., 114, 761-768.
24. 1 receptor in vivo. Br. J. Pharmacol., 116, 1957-1964.
25. 6-cyclopentyladenosine in the rat. J. Pharmacol. Exp. Ther., 268, 616-624.
26. MERKEL, L.A., HAWKINS, E.D., COLUSSI, D.J., GREENLAND, B.D., SMITS, G.J., PERRONE, M.H. & COX, B.F. (1995). Cardiovascular and antilipolytic effects of the adenosine agonist GR79236. Pharmacology, 51, 224-236.
27. RANDLE, P.J., HALES, C.N., GARLAND, P.B. & NEWSHOLME, E.A. (1969). The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances in diabetes mellitus. Lancet, 1, 785-789.
28. REAVEN, G.M., CHANG, H., HO, H., JENG, C.I. & HOFFMAN, B. (1988). Lowering of plasma glucose in diabetic rats by antilipolytic agents. Am. J. Physiol., 254, E23-30.
29. REAVEN, G.M. & CHEN, Y.-D.I. (1988). Role of abnormal free fatty acid metabolism in the development of non-insulin dependent diabetes mellitus. Am. J. Med., 85, 106-112.
30. SALORANTA, C., FRANSILLA-KALLUNKI, A., EKSTRAND, A., TASKINEN, M.-R. & GROOP, L. (1991). Modulation of hepatic glucose production by non-esterified fatty acids in type 2 (non-insulin dependent) diabetes mellitus. Diabetologia, 34, 409-415.
31. STRONG, P., ANDERSON, R., COATES, J., ELLIS, F., EVANS, B., GURDEN, M.F., JOHNSTONE, J., KENNEDY, I. & MARTIN, D.P. (1993). Suppression of non esterified fatty acids and triacylglycerol in experimental animals by the adenosine analogue GR79236. Clin. Sci., 84, 663-669.
32. VAN GRIENSVEN, J.M.T., JUSKO, W.J., LEMKES, H.H.P.J., KROON, R., VERHORST, C.J., CHIANG, S.T. & COHEN, A.F. (1995). Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes. Clin. Pharmacol. Ther., 58, 631-640.
33. WALD, J.A., SALAZAR, D.E., CHENG, H. & JUSKO, J.W. (1992). Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics. J. Pharmacokinet. Biopharm., 19, 521-536.
34. WILLIAMSON, D.H. & HELLANBY, J. (1974). D-(-)-3-hydroxybutyrate. In Methods of Enzymatic Analysis. Vol. 4. ed. Bergmeyer, H.U. pp. 1836-1839. New York: Academic Press.